BIA 5-1058
Sponsors
Bial - Portela C S.A., Bial Portela & Ca.
Conditions
Cardiovascular DiseaseCardiovascular Disease+Pulmonary DiseaseHeart FailureHypertension and Chronic Heart FailurePulmonary Arterial Hypertensioncardiovascular diseases
Phase 1
Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.
CompletedNCT02151994
Start: 2011-03-31End: 2012-01-31Updated: 2016-01-05
Effect of BIA 5 1058 on Cardiac Repolarization
CompletedNCT03489005
Start: 2018-04-09End: 2018-10-05Updated: 2020-12-31
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058
CompletedNCT03708146
Start: 2018-05-28End: 2019-03-18Updated: 2020-12-31
Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil
CompletedNCT04675944
Start: 2018-02-28End: 2018-05-25Updated: 2020-12-19
Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058
TerminatedNCT04991194
Start: 2015-10-12End: 2016-12-30Updated: 2021-08-05
Effect of Food on BIA 5-1058
CompletedNCT04991155
Start: 2015-07-20End: 2015-09-22Updated: 2021-08-05
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
CompletedNCT04991207
Start: 2018-02-06End: 2018-05-14Updated: 2021-08-05
Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
CompletedNCT04994119
Start: 2018-02-23End: 2018-05-23Updated: 2021-08-06
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
CompletedNCT04994860
Start: 2018-03-22End: 2018-06-07Updated: 2021-08-06
Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide
CompletedNCT07173738
Start: 2018-06-11End: 2018-09-07Updated: 2025-09-15